Legend Biotech Corp Virtual Investor KOL Event Reviewing Latest CARTITUDE-1 Data from ASH Annual Meeting Transcript
Good evening. Welcome to Legend Biotech's webinar today to discuss our CARTITUDE-1 Phase Ib and II results in relapse or refractory multiple myeloma patients, which was presented at the American Society of Hematology on Saturday, December 5. I am Jessie Yeung, Head of Corporate Finance and Investor Relations at Legend Biotech.
Before we dive into the program, some housekeeping reminders. Today's call is being recorded and webcast on our website and will be available for replay. (Operator Instructions) Please submit any questions through the chat at any time during the event.
Before we get started, I would like to note that we posted a press release that provides the details of this data, which was presented at ASH 2020.
In terms of the format, we will begin with a brief overview of Legend Biotech, followed by data discussion and moderated Q&A session with our KOLs, and then we will open the floor for questions from the audience.
On the call today, we have Dr. Ying Huang, CEO of Legend
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
